Epidermal overexpression of transgenic Δnp63 promotes type 2 immune and myeloid inflammatory responses and hyperplasia via NF-κB activation

Journal of Pathology

Volumn 232, Issue 3, 2014, Pages 356-368

  Du, Jihui ^a,b   Romano, Rose Anne ^c   Si, Han ^a   Mattox, Austin ^a   Bian, Yansong ^a   Yang, Xinping ^a   Sinha, Satrajit ^c   Van Waes, Carter ^a   Chen, Zhong ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b Shenzhen Nanshan People s Hospital and the 6th Affiliated Hospital of Shenzhen University Medical School   (China)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

p63; chemokines; cytokines; infiltrating cells; NF B; transgenic mouse

Indexed keywords

CD11B ANTIGEN; CD11B+ MACROPHAGE; CD19 ANTIGEN; CD206 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; CELL PROTEIN; CHEMOKINE; CREL PROTEIN; CYTOKINE; F4/80+ ANTIGEN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; LY6B+ ANTIGEN; LYMPHOCYTE SURFACE MARKER; M2 CYTOKINE; NP63 PROTEIN; PROTEIN S 100; S 100+ ANTIGEN; TH2 CYTOKINE; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; B LYMPHOCYTE; CD19+ B LYMPHOCYTE; CD206+ MACROPHAGE; CD25 + NEUTROPHIL; CD3+ T HELPER CELL; CD3+ T LYMPHOCYTE; CD45+ LEUKOCYTE; CD68+ MACROPHAGE; CELL HYPERPLASIA; CONTROLLED STUDY; DENDRITIC CELL; DERMATITIS; EPIDERMIS; F4/80+ MACROPHAGE; FOXP3+ NEUTROPHIL; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HELPER CELL; HOST CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY INFILTRATE; LEUKOCYTE; LY6B+ NEUTROPHIL; LYMPHOCYTIC INFILTRATION; M2 CELL; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; NP63 GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; S 100+ DENDRITIC CELL; SECONDARY IMMUNE RESPONSE; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TH2 CELL; TRANSGENE; TRANSGENIC MOUSE;

EID: 84892380785     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4302     Document Type: Article

References (68)

1. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
2. Mantovani A, Allavena P, Sica A, et al., Cancer-related inflammation. Nature 2008; 454: 436-444.
3. Lin WW, Karin M,. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-1183.
4. Paul WE, Zhu J,. How are T(H)2-type immune responses initiated and amplified? Nature Rev Immunol 2010; 10: 225-235.
5. Sethi G, Shanmugam MK, Ramachandran L, et al., Multifaceted link between cancer and inflammation. Biosci Rep 2012; 32: 1-15.
6. Balkwill FR,. The chemokine system and cancer. J Pathol 2012; 226: 148-157.
7. Grivennikov SI, Karin M,. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011; 70 (Suppl 1): i104-108.
8. Wang F, Arun P, Friedman J, et al., Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol 2009; 9: 389-395.
9. Van Waes C., Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007; 13: 1076-1082.
10. Hayden MS, Ghosh S,. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012; 26: 203-234.
11. Hayden MS, Ghosh S,. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344-362.
12. Solt LA, May MJ,. The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol Res 2008; 42: 3-18.
13. Perkins ND,. The diverse and complex roles of NF-kappaB subunits in cancer. Nature Rev Cancer 2012; 12: 121-132.
14. Greten FR, Eckmann L, Greten TF, et al., IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-296.
15. Lu H, Yang X, Duggal P, et al., TNF-alpha promotes c-REL/DeltaNp63alpha interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer. Cancer Res 2011; 71: 6867-6877.
16. Yang X, Lu H, Yan B, et al., DeltaNp63 versatilely regulates a broad NF-kappaB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res 2011; 71: 3688-3700.
17. Deyoung MP, Ellisen LW,. p63 and p73 in human cancer: defining the network. Oncogene 2007; 26: 5169-5183.
18. Lanza M, Marinari B, Papoutsaki M, et al., Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutants. Cell Cycle 2006; 5: 1996-2004.
19. Romano RA, Ortt K, Birkaya B, et al., An active role of the DeltaN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One 2009; 4: e5623.
20. Romano RA, Sinha S,. Dynamic life of a skin keratinocyte: an intimate tryst with the master regulator p63. Indian J Exp Biol 2011; 49: 721-731.
21. Romano RA, Smalley K, Magraw C, et al., DeltaNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development 2012; 139: 772-782.
22. Romano RA, Smalley K, Liu S, et al., Abnormal hair follicle development and altered cell fate of follicular keratinocytes in transgenic mice expressing DeltaNp63alpha. Development 2010; 137: 1431-1439.
23. Chen Z, Colon I, Ortiz N, et al., Effects of interleukin-1alpha, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines. Cancer Res 1998; 58: 3668-3676.
24. Chen Z, Malhotra PS, Thomas GR, et al., Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999; 5: 1369-1379.
25. Schuler PJ, Schilling B, Harasymczuk M, et al., Phenotypic and functional characteristics of CD4(+) CD39(+) FOXP3(+) and CD4(+) CD39(+) FOXP3(neg) T-cell subsets in cancer patients. Eur J Immunol 2012; 42: 1876-1885.
26. Vukmanovic-Stejic M, Rustin MH, Nikolich-Zugich J, et al., Immune responses in the skin in old age. Curr Opin Immunol 2011; 23: 525-531.
27. Junankar SR, Eichten A, Kramer A, et al., Analysis of immune cell infiltrates during squamous carcinoma development. J Invest Dermatol Symp Proc 2006; 11: 36-43.
28. Liu Y, Zhang P, Li J, et al., A critical function for TGF-beta signaling in the development of natural CD4 + CD25 + Foxp3+ regulatory T cells. Nature Immunol 2008; 9: 632-640.
29. Honda T, Miyachi Y, Kabashima K,. Regulatory T cells in cutaneous immune responses. J Dermatol Sci 2011; 63: 75-82.
30. Oh JE, Kim RH, Shin KH, et al., DeltaNp63alpha protein triggers epithelial-mesenchymal transition and confers stem cell properties in normal human keratinocytes. J Biol Chem 2011; 286: 38757-38767.
31. Biswas SK, Mantovani A,. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunol 2010; 11: 889-896.
32. Mantovani A, Sica A,. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010; 22: 231-237.
33. Han G, Li F, Singh TP, et al., The pro-inflammatory role of TGFbeta1: a paradox? Int J Biol Sci 2012; 8: 228-235.
34. Biswas SK, Lewis CE,. NF-kappaB as a central regulator of macrophage function in tumors. J Leukoc Biol 2010; 88: 877-884.
35. Sica A, Schioppa T, Mantovani A, et al., Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717-727.
36. Hallam S, Escorcio-Correia M, Soper R, et al., Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol 2009; 219: 143-152.
37. Mburu YK, Egloff AM, Walker WH, et al., Chemokine receptor 7 (CCR7) gene expression is regulated by NF-kappaB and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN). J Biol Chem 2012; 287: 3581-3590.
38. Duffey DC, Chen Z, Dong G, et al., Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999; 59: 3468-3474.
39. He R, Oyoshi MK, Garibyan L, et al., TSLP acts on infiltrating effector T cells to drive allergic skin inflammation. Proc Natl Acad Sci U S A 2008; 105: 11875-11880.
40. Zaph C, Troy AE, Taylor BC, et al., Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature 2007; 446: 552-556.
41. Gabrilovich DI, Nagaraj S,. Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev Immunol 2009; 9: 162-174.
42. Loukinova E, Dong G, Enamorado-Ayalya I, et al., Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 2000; 19: 3477-3486.
43. Bancroft CC, Chen Z, Dong G, et al., Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 2001; 7: 435-442.
44. Young MR, Petruzzelli GJ, Kolesiak K, et al., Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. Hum Immunol 2001; 62: 332-341.
45. Waugh DJ, Wilson C,. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-6741.
46. Koster MI, Dai D, Marinari B, et al., p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci U S A 2007; 104: 3255-3260.
47. Freudlsperger C, Bian Y, Contag Wise S, et al., TGF-beta and NF-kappaB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers. Oncogene 2013; 32: 1549-1559.
48. Nottingham LK, Yan CH, Yang X, et al., Aberrant IKKalpha and IKKbeta cooperatively activate NF-kappaB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. Oncogene 2013; DOI: 10.1038/onc.2013.49.
49. King KE, Ponnamperuma RM, Allen C, et al., The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth. Cancer Res 2008; 68: 5122-5131.
50. Rebel HG, Bodmann CA, van de Glind GC, et al., UV-induced ablation of the epidermal basal layer including p53-mutant clones resets UV carcinogenesis showing squamous cell carcinomas to originate from interfollicular epidermis. Carcinogenesis 2012; 33: 714-720.
51. Stiewe T., The p53 family in differentiation and tumorigenesis. Nature Rev Cancer 2007; 7: 165-168.
52. Harmes DC, Bresnick E, Lubin EA, et al., Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes. Oncogene 2003; 22: 7607-7616.
53. Rangwala S, Tsai KY,. Roles of the immune system in skin cancer. Br J Dermatol 2011; 165: 953-965.
54. Allen C, Duffy S, Teknos T, et al., Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 2007; 13: 3182-3190.
55. DiDonato JA, Mercurio F, Karin M,. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012; 246: 379-400.
56. Keeley EC, Mehrad B, Strieter RM,. CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 2010; 106: 91-111.
57. Loukinova E, Chen Z, Van Waes C, et al., Expression of proangiogenic chemokine Gro 1 in low and high metastatic variants of Pam murine squamous cell carcinoma is differentially regulated by IL-1alpha, EGF and TGF-beta1 through NF-kappaB dependent and independent mechanisms. Int J Cancer 2001; 94: 637-644.
58. Oeckinghaus A, Hayden MS, Ghosh S,. Crosstalk in NF-kappaB signaling pathways. Nature Immunol 2011; 12: 695-708.
59. Diamond I, Owolabi T, Marco M, et al., Conditional gene expression in the epidermis of transgenic mice using the tetracycline-regulated transactivators tTA and rTA linked to the keratin 5 promoter. J Invest Dermatol 2000; 115: 788-794.
60. Brenner JC, Graham MP, Kumar B, et al., Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 2010; 32: 417-426.
61. Lee TL, Yang XP, Yan B, et al., A novel nuclear factor-{kappa}B gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 2007; 13: 5680-5691.
62. Yan B, Yang X, Lee TL, et al., Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-kappaB and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol 2007; 8: R78.
63. Friedman J, Nottingham L, Duggal P, et al., Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Clin Cancer Res 2007; 13: 6568-6578.
64. Rocco JW, Leong CO, Kuperwasser N, et al., p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9: 45-56.
65. Starczynowski DT, Reynolds JG, Gilmore TD,. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells. Oncogene 2003; 22: 6928-6936.
66. Mori N, Mukaida N, Ballard DW, et al., Human T-cell leukemia virus type I Tax transactivates human interleukin 8 gene through acting concurrently on AP-1 and nuclear factor-kappaB-like sites. Cancer Res 1998; 58: 3993-4000.
67. Squarize CH, Castilho RM, Sriuranpong V, et al., Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 2006; 8: 733-746.
68. Thurfjell N, Coates PJ, Vojtesek B, et al., Endogenous p63 acts as a survival factor for tumour cells of SCCHN origin. Int J Mol Med 2005; 16: 1065-1070.